Combinations to treat cancer

A method of treating a wild-type BRAF tumor in a subject comprising administering to the subject a DNA damaging agent and a pan-RAF inhibitor, wherein the tumor is a pancreatic tumor, melanoma tumor, or colon cancer tumor, wherein the pan-RAF inhibitor is 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine (RAF265), 3-(2-cyanopropan-2-yl)-N-[4-methyl-3[(3-methyl-4-oxoquinazolin-6-yl)amino]phenyl]benzamide (AZ628), 1-(3,3-dimethylbutyl)-3-[2-fluoro-4-methyl-5-[7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl]phenyl]urea (LY3009120), N-[7-Cyano-6-[4-fluoro-3-[[2-[3-(trifluoromethyl)phenyl]acetyl]amino]phenoxy]-1,3-benzothiazol-2-1]cyclopropanecarboxamide (TAK632), 2-[(1R)-1-[(6-Amino-5-chloropyrimidine-4-carbonyl)amino]ethyl]-N-[5-chloro-4-(trifluoromethyl)pyridin-2-yl]-1,3-thiazole-5-carboxamide (MLN2480), N-[3-[5-[(1-Ethylpiperidin-4-yl)-methylamino]-3-pyrimidin-5-ylpyrrolo[3,2-b]pyridin-1-yl]-2,4-difluorophenyl]propane-1-sulphonamide (XP102), or a pharmaceutically acceptable salt thereof, and wherein the DNA damaging agent is gemcitabine, 5-fluorouracil, cytarabine, methotrexate, pyrimethamine, bleomycin, oxaliplatin, cisplatin, carboplatin, etoposide, doxorubicin, vinorelbin, mitoxantrone, podophyllotoxin, aphidicolin, fotemustine, carmustine, [(5S,6S)-6-Acetyloxy-11-methoxy-2,7,7-trimethyl-13-oxo-8-oxa-2-azapentacyclo[12.8.0.03,12.04,9.016,21]docosa-1(22),3,9,11,14,16,18,20-octaen-5-yl] acetate (S-23906), (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015.20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione(SN-38), topotecan, camptothecin, rebeccamiycin, or any pharmaceutically acceptable salt thereof.